ClinicalTrials.gg
AvailableNCT06188975Updated Jan 3, 2024

Expanded Access to ABBV-CLS-484

An expanded access record providing DRUG: ABBV-CLS-484 in Advanced Solid Tumor Cancer, sponsored by Calico Life Sciences LLC. Available. Per ClinicalTrials.gov, last updated 2024-01-03.

Sponsored by Calico Life Sciences LLC · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
01

Study summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

02

Conditions studied

  • Advanced Solid Tumor Cancer
03

In context

Lead sponsor

Calico Life Sciences LLC is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)

Eligibility criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • DrugDRUG: ABBV-CLS-484
06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT06188975
Lead sponsor
Calico Life Sciences LLC
Responsible party
Sponsor
First posted
Jan 3, 2024
Last update
Jan 3, 2024

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
847.283.8955
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion